近期上交所联合有关部门先后在上海、北京等地举办科创板改革"1+6"政策宣介会，正式启动在全国重 点省市以及科技企业聚集地的系列宣贯活动。地方金融、科技、经信等相关部门、重点园区，上海、北 京证监局，200余家重点科创企业以及证券公司代表，共420余人参会。 ...

除此之外，我们也可以看到今天券商终于收红了，我们说这个券商想止跌要先出个红星。今天啊能起到 一个红星止跌的作用，那么才有可能引发波动啊攻击。那么一旦券商只要动一下，那么整个大盘就会站 到3500点，到了3500点上方，3670这个套牢盘就是下一个解放的目标。所以说我们现在的大盘，我认为 它在蓄势的概率比较大，我们要做的就是耐心的等待它的这个最终的突破性 K线出现。 今天的大盘又是一个小阴小阳星的震荡，那么大盘能不能突破3450？和讯投顾王海洋表示，从今天的表 现来看的话，大盘极有可能会选择中阳突破3450 3500点，那么去挑战3650这一带的万亿套牢盘的释 放。那么今天大盘虽然没有大涨，但是这个地方能够在这个地方停留一周多，也就说明这个地方主力在 尝试着叙事，那么现在就差一个突破性的k线，那么为什么说这个地方大概率可能会产生突破？那么具 体的我们切换到指数的走势来看，今天上证指数虽然是个小阳星，没有创造新高，没有实质性突破，但 是我们可以看到深证指数已经率先突破，已经创了新高，创业板也创了新高，而且是一个没有放什么量 的新高，那么这个地方各大指数，尤其是创业板和深证都有一个创新高的动作，而且科创板这个今天也 ...

Group 1 - The stock of Hangke Technology (688006) has a comprehensive score of 63.46, indicating a strong performance [1] - The main cost analysis shows that the current main cost is 19.55 yuan, with a 5-day average of 19.46 yuan and a 20-day average of 18.78 yuan [1] - There have been no instances of the stock hitting the upper or lower limits in the past year [1] Group 2 - On July 3, 2025, the net inflow of main funds was 12.22 million yuan, accounting for 9% of the total transaction amount [2] - The short-term pressure level is at 19.62 yuan, while the short-term support level is at 19.21 yuan [2] - The stock is associated with several sectors, including batteries (1.98%), solid-state batteries (1.91%), and lithium batteries (1.08%) [2]

Core Insights - The average stock price of the Sci-Tech Innovation Board is 30.77 yuan, with 39 stocks priced over 100 yuan, the highest being Cambricon at 547.30 yuan [1][2] - A total of 365 stocks increased in price today, while 208 stocks decreased, with the average increase for stocks over 100 yuan being 0.34% [1][2] - The average premium of stocks over their issue price for those priced over 100 yuan is 327.13%, with notable premiums for companies like Anji Technology and Baile Tianheng [1][2] Stock Performance - Cambricon closed at 547.30 yuan, up 0.40%, followed by Baile Tianheng at 298.00 yuan and Huitai Medical at 294.38 yuan [1][2] - Among the stocks priced over 100 yuan, 23 stocks increased, with the largest gainers being Hotgen Biotech, Zexin Pharmaceutical, and Naxin Micro [1][2] - The stocks with the largest declines included Longxin Technology, Sirepu, and Zhongke Lanyun [1][2] Industry Distribution - The stocks priced over 100 yuan are concentrated in the electronics, pharmaceutical, and computer industries, with 20, 8, and 5 stocks respectively [1][2] - The total net outflow of main funds from stocks priced over 100 yuan today was 5.46 billion yuan, with notable inflows into companies like Siterui and Zexin Pharmaceutical [2] - The total financing balance for stocks priced over 100 yuan is 26.624 billion yuan, with Cambricon leading at 4.478 billion yuan [2][3]

Core Viewpoint - CloudBreak Therapeutics has successfully listed on the Hong Kong Stock Exchange, marking a significant milestone as the first international ophthalmic innovation drug company to go public in Hong Kong, with a market capitalization of HKD 84.73 billion and net fundraising of approximately HKD 5.22 billion [2][4] Company Overview - Founded in 2015 in Irvine, California, CloudBreak Therapeutics is a clinical ophthalmic biotechnology company focused on innovative and differentiated therapies, with a mission to ensure that no one is hindered by poor eye health [4] - The company has developed a broad and innovative pipeline, including eight drug candidates targeting major diseases of the anterior and posterior segments of the eye, with four in clinical stages and four in preclinical stages [4] Product Pipeline - The core product CBT-001 is a pioneering drug for the treatment of pterygium, currently undergoing global Phase III clinical trials across multiple countries, showing significant efficacy and good tolerability [6][10] - Other products in the pipeline include CBT-004 for treating vascularized pterygium, CBT-006 for dry eye syndrome, and CBT-009 for myopia in adolescents, all demonstrating promising clinical results [12][13] Market Opportunity - The global prevalence of pterygium is 10.2%, with rural areas in China reaching as high as 33%, indicating a significant unmet medical need in this area [7][10] - The global ophthalmic drug market is projected to reach USD 73.9 billion by 2030, highlighting the growth potential for innovative therapies in this sector [16] Investment and Support - Since 2018, CloudBreak Therapeutics has raised a total of HKD 11.3 billion, receiving support from various institutions, including Yi Feng Capital, which participated in its C-round financing in 2022 [14][15] - The successful IPO is seen as a validation of the company's core value and clear development path, with expectations for its innovative products to capture significant market share in the global ophthalmic drug market [15][18]

聚焦股权投资行业人物、事件、数据、研究、政策解读，提供专业视角和深度洞见 | 创投圈有趣的灵魂 将投中网设为"星标⭐"，第一时间收获最新推送 生物医药又要成为投资人"香饽饽"了？ 作者丨 陈美 来源丨 东四十条资本 对于未盈利科创企业，证监会正在大力支持。 以下文章来源于东四十条资本 ，作者陈美 东四十条资本 . 在他看来，过去两年，生物医药行业经历了资本寒冬，不少企业只能依靠BD交易获取现金流。如今 第五套标准的重启，让生物医药这一长周期、需要大资金支持的行业，再次看到希望。 "这不仅是行业和投资层面的利好，更是国家对生物医药行业的重视。"该投资人说。 CVSource投中数据显示，禾元生物于2022年12月获科创板受理，至今已排队两年多时间。期间， 公司经历了两轮问询，以及多次财务资料过期、中止上市审核等情况。 投资人聚焦：第五套标准是否提高？ 禾元生物的过会，显然给行业打了一剂强心针，但投资人最关心的，还是"审核标准"是否提高，上 市窗口期究竟有多长？ 在朗盛投资合伙人李佳看来，禾元生物的过会，打开了生物医药企业上市的口子，但政策稳定性、持 续性则是投资人最关心的。毕竟，生物医药行业是长周期、重资本行业 ...

Group 1 - The Shanghai Stock Exchange Sci-Tech Innovation Board 50 Index (Sci-Tech 50) opened higher and fluctuated, rising by 0.24% to 984.95 points with a trading volume of 19.704 billion yuan [1] - Over the past month, the Sci-Tech 50 Index has increased by 0.57%, but it has decreased by 3.92% over the past three months and by 0.64% year-to-date [2] - The Sci-Tech 50 Index consists of 50 securities with high market capitalization and liquidity from the Sci-Tech Innovation Board, reflecting the overall performance of representative Sci-Tech enterprises [2] Group 2 - The top ten weighted stocks in the Sci-Tech 50 Index are: SMIC (10.35%), Haiguang Information (8.5%), Cambricon (7.68%), Lattice Semiconductor (6.2%), Zhongwei Company (5.28%), Kingsoft Office (4.24%), United Imaging (4.21%), Transsion Holdings (2.35%), Chipone Technology (2.27%), and Ninebot (2.27%) [2] - The index is fully composed of stocks listed on the Shanghai Stock Exchange, with the information technology sector accounting for 68.86%, healthcare for 11.91%, industrials for 11.41%, consumer discretionary for 4.45%, materials for 2.72%, and consumer staples for 0.66% [2] Group 3 - The sample of the Sci-Tech 50 Index is adjusted quarterly, with adjustments occurring on the next trading day after the second Friday of March, June, September, and December [3] - The adjustment process allows for a maximum of 10% change in the number of samples, with a buffer rule prioritizing the top 40 candidates for inclusion and the top 60 existing samples for retention [3] - In cases of sample delisting, mergers, or other changes, the index will follow specific guidelines for replacement and adjustment [3]

Group 1 - Cloudbreak Pharma Inc. (stock code 2592.HK) officially listed on the Hong Kong Stock Exchange on July 3, 2025, with an IPO price of HKD 10.10 per share, achieving nearly 78 times oversubscription [1] - The IPO project received cornerstone investment of approximately USD 2.8 million from The Reynold Lemkins Group (Asia) Limited, facilitated by the professional recommendations of the Baihui Financial team [1] - The global offering consisted of approximately 60.582 million shares, with a subscription period from June 24 to June 27, 2025, and an expected net fundraising amount of up to HKD 610 million [1] Group 2 - The company plans to allocate the proceeds from the IPO as follows: approximately 62.4% for ongoing clinical research and development of core product CBT-001, about 27.6% for costs related to ongoing clinical research and registration of CBT-009, around 5.5% for production facilities and commercialization activities, and the remaining 4.5% for working capital and other general corporate purposes [3] - CBT-001 is the world's first innovative drug for pterygium entering Phase III clinical trials, targeting VEGFR and PDGFR to precisely regulate abnormal vascular growth on the ocular surface [8] - As of May 2025, CBT-001 has completed patient enrollment in multi-center Phase III clinical trials in China, the United States, and Australia, with plans to submit dual market applications in China and the U.S. in 2025 [8] Group 3 - Baihui Financial anticipates that with CBT-004 completing Phase II clinical trials in the U.S., CBT-001 is expected to be launched in 2026, marking the company's transition from a research-driven entity to a commercialization phase [10] - The company plans to establish sales branches in major global markets within the next three years while accelerating the clinical advancement of CBT-009, aiming to build a differentiated competitive advantage in the field of ophthalmic innovative drugs through technological innovation and global expansion [10]

深证成指收报10534.58点，涨1.17%。 创业板指收报2164.09点，涨1.90%。 沪深300收报3968.07点，涨0.62%。 科创50收报984.95点，涨0.24%。 中证500收报5922.66点，涨0.50%。 中证1000收报6342.64点，涨0.53%。 上证指数收报3461.15点，涨0.18%。 ...

Market Performance Summary - The Shanghai Composite Index closed at 3461.15 points, up by 6.36 points, representing a gain of 0.18% on July 3 [1] - The Shenzhen Component Index closed at 10534.58 points, increasing by 121.96 points, with a rise of 1.17% on July 3 [1] - The CSI 300 Index ended at 3968.07 points, up by 24.38 points, reflecting a growth of 0.62% on July 3 [1] - The ChiNext Index closed at 2164.09 points, rising by 40.37 points, which corresponds to a 1.9% increase on July 3 [1] - The STAR 50 Index finished at 984.95 points, up by 2.31 points, marking a gain of 0.24% on July 3 [1]